DK3891156T3 - Nye krystallinske former af et thienopyrimidin som mcl-1-inhibitor - Google Patents

Nye krystallinske former af et thienopyrimidin som mcl-1-inhibitor Download PDF

Info

Publication number
DK3891156T3
DK3891156T3 DK19817229.8T DK19817229T DK3891156T3 DK 3891156 T3 DK3891156 T3 DK 3891156T3 DK 19817229 T DK19817229 T DK 19817229T DK 3891156 T3 DK3891156 T3 DK 3891156T3
Authority
DK
Denmark
Prior art keywords
thienopyrimidine
mcl
inhibitor
crystalline forms
new crystalline
Prior art date
Application number
DK19817229.8T
Other languages
Danish (da)
English (en)
Inventor
Baets Emilie De
Julien Auvray
Michael Lynch
Nicolas Leblanc
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Application granted granted Critical
Publication of DK3891156T3 publication Critical patent/DK3891156T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19817229.8T 2018-12-06 2019-12-05 Nye krystallinske former af et thienopyrimidin som mcl-1-inhibitor DK3891156T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18306634 2018-12-06
PCT/EP2019/083773 WO2020115183A1 (en) 2018-12-06 2019-12-05 New crystalline forms of a mcl-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them.

Publications (1)

Publication Number Publication Date
DK3891156T3 true DK3891156T3 (da) 2024-02-19

Family

ID=64665802

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19817229.8T DK3891156T3 (da) 2018-12-06 2019-12-05 Nye krystallinske former af et thienopyrimidin som mcl-1-inhibitor

Country Status (26)

Country Link
US (2) US12129261B2 (cg-RX-API-DMAC7.html)
EP (1) EP3891156B1 (cg-RX-API-DMAC7.html)
JP (1) JP7649241B2 (cg-RX-API-DMAC7.html)
KR (1) KR102855345B1 (cg-RX-API-DMAC7.html)
CN (1) CN113166169A (cg-RX-API-DMAC7.html)
AR (1) AR117255A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019391329B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021010072A2 (cg-RX-API-DMAC7.html)
CA (1) CA3121363A1 (cg-RX-API-DMAC7.html)
DK (1) DK3891156T3 (cg-RX-API-DMAC7.html)
EA (1) EA202191534A1 (cg-RX-API-DMAC7.html)
ES (1) ES2971258T3 (cg-RX-API-DMAC7.html)
FI (1) FI3891156T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240211T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065266T2 (cg-RX-API-DMAC7.html)
IL (1) IL283656B2 (cg-RX-API-DMAC7.html)
LT (1) LT3891156T (cg-RX-API-DMAC7.html)
MA (1) MA54379B1 (cg-RX-API-DMAC7.html)
MD (1) MD3891156T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006702A (cg-RX-API-DMAC7.html)
PL (1) PL3891156T3 (cg-RX-API-DMAC7.html)
PT (1) PT3891156T (cg-RX-API-DMAC7.html)
RS (1) RS65047B1 (cg-RX-API-DMAC7.html)
SI (1) SI3891156T1 (cg-RX-API-DMAC7.html)
TW (1) TWI905090B (cg-RX-API-DMAC7.html)
WO (1) WO2020115183A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7900421B2 (ja) 2021-06-11 2026-08-04 ギリアード サイエンシーズ, インコーポレイテッド Mcl-1阻害剤と抗がん剤との組み合わせ
TWI861509B (zh) 2021-06-11 2024-11-11 美商基利科學股份有限公司 Mcl-1抑制劑與抗體藥物接合物之組合

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037957B1 (fr) 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3046792B1 (fr) 2016-01-19 2018-02-02 Les Laboratoires Servier Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
KR20210100148A (ko) 2021-08-13
IL283656B1 (en) 2025-06-01
TW202039511A (zh) 2020-11-01
PT3891156T (pt) 2024-01-16
AU2019391329A1 (en) 2021-07-01
MA54379A (fr) 2021-10-13
SI3891156T1 (sl) 2024-03-29
CN113166169A (zh) 2021-07-23
TWI905090B (zh) 2025-11-21
HUE065266T2 (hu) 2024-05-28
EA202191534A1 (ru) 2021-10-27
PL3891156T3 (pl) 2024-05-13
RS65047B1 (sr) 2024-02-29
JP2022511495A (ja) 2022-01-31
JP7649241B2 (ja) 2025-03-19
BR112021010072A2 (pt) 2021-08-24
WO2020115183A1 (en) 2020-06-11
LT3891156T (lt) 2023-12-27
ES2971258T3 (es) 2024-06-04
HRP20240211T1 (hr) 2024-04-26
AU2019391329B2 (en) 2024-09-26
AR117255A1 (es) 2021-07-21
IL283656B2 (en) 2025-10-01
EP3891156A1 (en) 2021-10-13
US20250011337A1 (en) 2025-01-09
MD3891156T2 (ro) 2024-06-30
EP3891156B1 (en) 2023-11-15
NZ776907A (en) 2025-05-02
US12129261B2 (en) 2024-10-29
MA54379B1 (fr) 2023-12-29
CA3121363A1 (en) 2020-06-11
MX2021006702A (es) 2021-07-07
US20220017533A1 (en) 2022-01-20
IL283656A (en) 2021-07-29
FI3891156T3 (fi) 2024-02-07
KR102855345B1 (ko) 2025-09-03

Similar Documents

Publication Publication Date Title
EP4029868B1 (en) MCL-1 INHIBITORS
DK3972960T3 (da) Krystallinske former af en btk-hæmmer
DK3472157T3 (da) Krystallinske faste former af en bet-inhibitor
DK3837263T3 (da) Nye heterocykliske forbindelser som monoacylglycerollipasehæmmere
DK3541807T3 (da) Krystallinsk form af en magl-inhibitor
DK3464272T3 (da) Nye heterocykliske derivater som SHP2-inhibitorer
DK3334709T3 (da) Salte af en lsd1-hæmmer
IL286218A (en) Solid state forms of ripretinib
DK3551627T3 (da) Nye isoxazolyletherderivater som gaba a alpha5-pam
DK3774862T3 (da) Nye GLP-1-analoger
DK3762368T3 (da) Aminopyrazindiolforbindelser som pi3k-y-inhibitorer
DK3894012T3 (da) Krystallinske former og saltformer af en kinasehæmmer
DK3826982T3 (da) Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer
DK4114826T3 (da) Krystallinske former af en farmaceutisk forbindelse
DK3833665T3 (da) Diazabicyclooctanoner som hæmmere af serin-beta-lactamaser
IL282454A (en) Crystalline salts of a plasma kallikrein inhibitor
EP3393458A4 (en) METHOD OF USE OF A CLASS IIA HDAC HEMMER
DK3826983T3 (da) Anvendelse af substituerede 2-thiazoliner som nitrificeringshæmmere
DK3749673T3 (da) Krystallinsk form af bictegravir-natrium
AR104935A1 (es) Formas cristalinas de un inhibidor de histona deacetilasa
DK3630725T3 (da) Krystallinsk form af n-butyldeoxygalactonojirimycin
PL3891156T3 (pl) Nowe krystaliczne formy inhibitora MCL-1, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne
HUE062106T2 (hu) Peptid-epoxiketon-immunoproteaszóma inhibitor kristályos sói
DK3459538T3 (da) Krystallinske salte af et dextroamfetamin-prodrug
DK3924361T3 (da) Nye triterpenderivater som hiv-hæmmere